Article Versions Notes

Vannucchi AM, Mortara A, D’Alessio A, Morelli M, Tedeschi A, Festuccia MB, Monforte AD, Capochiani E, Selleri C, Simonetti F, et al. JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy. Journal of Clinical Medicine. 2021; 10(16):3752. https://doi.org/10.3390/jcm10163752

Vannucchi, Alessandro Maria, Andrea Mortara, Andrea D’Alessio, Mara Morelli, Alberto Tedeschi, Moreno Benedetto Festuccia, Antonella D’Arminio Monforte, Enrico Capochiani, Carmine Selleri, Federico Simonetti, and et al. 2021. "JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy" Journal of Clinical Medicine 10, no. 16: 3752. https://doi.org/10.3390/jcm10163752

Vannucchi, A. M., Mortara, A., D’Alessio, A., Morelli, M., Tedeschi, A., Festuccia, M. B., Monforte, A. D., Capochiani, E., Selleri, C., Simonetti, F., Saracino, A., Rapezzi, D., Badagliacca, M. R., Falasca, K., Molteni, A., Palazzolo, R., Schettino, G., Bocchia, M., Turrini, M., ... Saglio, G. (2021). JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy. Journal of Clinical Medicine, 10(16), 3752. https://doi.org/10.3390/jcm10163752